Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Nov 25, 2024 4:15pm EST

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Nov 22, 2024 8:00am EST

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Nov 20, 2024 7:30am EST

Aptose Reports Results for the Third Quarter 2024

Nov 08, 2024 4:01pm EST

Aptose Announces Results from Special Meeting of Shareholders

Sep 05, 2024 4:15pm EDT

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aug 30, 2024 4:30pm EDT

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aug 15, 2024 4:30pm EDT

Aptose Reports Results for the Second Quarter 2024

Aug 08, 2024 5:06pm EDT

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Jul 19, 2024 5:00pm EDT

Aptose Announces Results from Annual and Special Meeting of Shareholders

Jun 18, 2024 5:30pm EDT